PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.\', \'Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.\', \'Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.\', \'Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.\', \'State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China.\', \'National Institute for Food and Drug Control (NIFDC), Beijing, China. Electronic address: huzy67@163.com.\', \'Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: yhxie@fudan.edu.cn.\', \'Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. Electronic address: liujn@cnilas.org.cn.\', \'Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China. Electronic address: liuge@walvax.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0264-410X(21)01399-210.1016/j.vaccine.2021.10.066
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34750014
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all